Arcturus Therapeutics (ARCT) PT Lowered to $33 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Arcturus Therapeutics (ARCT) PT Lowered to $93 at Brookline Capital Markets, Following Clinical Business Update
January 25, 2022 2:30 PM ESTBrookline Capital Markets analyst Kumaraguru Raja lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $93.00 (from $101.00) while maintaining a Buy rating.
Analyst says: "ARCT-154 and ARCT-165 (self-amplifying mRNA vaccines) are effective against SARS-CoV-2 virus variants, including Omicron and Delta. Results from the Phase 1/2... More
Arcturus Therapeutics (ARCT) Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
January 25, 2022 8:02 AM ESTArcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced new data from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting variants of concern.
This press release features multimedia. View the full release here:... More
Arcturus Therapeutics (ARCT) Reports Update Data from ARCT-154 and ARCT-165 Booster Trial, Demonstrates Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
January 24, 2022 8:07 AM ESTArcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced updated data from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting the variants of concern.
We continue to gather highly encouraging data from our next-generation, self-amplifying mRNA vaccine candidates ARCT-154 and ARCT-165 that have now both demonstrated encouraging neutralizing... More
